Rasche L, Kapp M, Einsele H, Mielke S. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transpl. 2014;49:163–7.

Article  CAS  Google Scholar 

Martinez OM, Krams SM. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder. Transplantation 2017;101:2009–16.

Article  PubMed  PubMed Central  Google Scholar 

Kinzel M, Dowhan M, Kalra A, Williamson TS, Dabas R, Jamani K, et al. Risk factors for the incidence of and the mortality due to post-transplant lymphoproliferative disorder after hematopoietic cell transplantation. Transplant Cell Ther. 2022,28:53.e1–10.

Article  Google Scholar 

Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 2014;99:346–52.

Article  PubMed  PubMed Central  Google Scholar 

Sundin M, Le Blanc K, Ringdén O, Barkholt L, Omazic B, Lergin C, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006;91:1059–67.

PubMed  Google Scholar 

Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, et al. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation. Clin Transplant. 2018;32:e13150.

Article  Google Scholar 

Kalra A, Williamson T, Daly A, Savoie ML, Stewart DA, Khan F, et al. Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2016;22:1654–63.

Article  CAS  Google Scholar 

Ugarte-Torres A, Hoegh-Petersen M, Liu Y, Zhou F, Williamson TS, Quinlan D, et al. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. Biol Blood Marrow Transpl. 2011;17:574–85.

Article  Google Scholar 

van der Heiden PLJ, van Egmond HM, Veld SAJ, van de Meent M, Eefting M, de Wreede LC, et al. CMV seronegative donors: Effect on clinical severity of CMV infection and reconstitution of CMV-specific immunity. Transpl Immunol. 2018;49:54–8.

Article  PubMed  Google Scholar 

Hoegh-Petersen M, Goodyear D, Geddes MN, Liu S, Ugarte-Torres A, Liu Y, et al. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Bone Marrow Transpl. 2011;46:1104–12.

Article  CAS  Google Scholar 

Djaoud Z, Guethlein LA, Horowitz A, Azzi T, Nemat-Gorgani N, Olive D, et al. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells. J Exp Med. 2017;214:1827–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hatton O, Strauss-Albee DM, Zhao NQ, Haggadone MD, Pelpola JS, Krams SM, et al. NKG2A-Expressing Natural Killer Cells Dominate the Response to Autologous Lymphoblastoid Cells Infected with Epstein-Barr Virus. Front Immunol. 2016;7:607.

Article  PubMed  PubMed Central  Google Scholar